Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?

Author(s) Idhrees A.M.; Suthakaran P.K.; Valooran G.J.; Bashir M.
Source International Journal of Angiology; Jun 2021; vol. 30 (no. 2); p. 155-159
Infection with the novel coronavirus, SARS-CoV2, produces the clinical syndrome COVID-19. COVID-19 is a systemic illness inducing hyperinflammation and cytokine storm affecting multiple organs including the myocardium which is reflected in elevated cardiac biomarkers such as troponin, lactate dehydrogenase, and creatinine kinase MB. Furthermore, COVID-19 has been implicated in increased predilection to thromboembolic phenomena. Hence, mortality in patients with associated cardiovascular disease has been higher compared with the cohort with no cardiovascular comorbidity. It is entirely unknown how remdesivir will change the facet of cardiovascular medicine and surgery. In the present constantly changing climate, this review of remdesivir and its association with cardiovascular disease is comprehensive as of June 17, 2020 and it highlights the science behind this drug and its potential implications to cardiovascular practice. Copyright © 2020. International College of Angiology. All rights reserved.

• Available in full text at The International journal of angiology : official publication of the International College of Angiology, Inc from Unpaywall